Onward Medical (ONWD) Company presentation summary

Company overview and vision

• Focuses on neuromodulation therapies to restore movement, function, and independence after spinal cord injury (SCI), leveraging three differentiated technology platforms: ARCEX, ARCIM, and ARCBCI.

• Holds over 150 issued patents and has received 10 FDA Breakthrough Device Designations.

• Addresses a $15B+ addressable market with limited competition and high unmet need, targeting both US and European markets.

• Vision centers on empowering people with SCI to enjoy life independently.

Market need and opportunity

• SCI affects approximately 650,000 people in the US and Europe and 9 million globally, with high lifetime costs per patient.

• Current standard-of-care does not restore lost function, leading to poor quality of life and significant unmet needs, including paralysis, blood pressure instability, and incontinence.

Growth strategy and pipeline

• Initial focus on near-term indications: ARCEX for hand sensation/strength and ARCIM for blood pressure instability, with pivotal trials underway.

• Plans for label and platform expansion into additional indications such as Parkinson's, stroke, and mobility, leveraging grant funding and investigator-initiated studies.

• Pipeline includes both commercial and investigational programs, with human proof-of-concept expected for new indications in 2026.